Relmada (RLMD): Price Target Chart
Relmada Therapeutics (RLMD) is developing its neurological pipeline through partnerships with clinics to create antidepressants. However, global conflicts and sanctions complicate international patient recruitment and the transport of biomaterials. This price chart on GURU.Markets featuring the 10.70 metric illustrates the asset's price action. Meanwhile, operations in the US and the humanitarian status of medicine minimize geopolitical risks, ensuring a stable legal framework.
Analytical breakdowns for Relmada (RLMD)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Relmada Therapeutics|RLMD - Long-Term Debt to Capital|Current Liabilities to Capital Relmada Corp|RLMD - Company Total Debt|Debts to Book Capitalization Relmada|RLMD - Company Long-Term Debt|Company Short-Term Loans and Borrowings Relmada Therapeutics|Immediate Liquidity relmada.com
- business earnings and investment ratios data:
RLMD - Company Net Income|Expected Net Income Relmada Therapeutics|RLMD - P/E Multiple|Projected Price to Earnings Ratio Relmada Therapeutics Inc|RLMD - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada|RLMD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Relmada Therapeutics|RLMD - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth relmada.com|RLMD - Earnings growth in current year|Projected earnings per share growth rate for next year Relmada Therapeutics
Summary company analytics:RLMD relmada.com
This indicator represents a weighted average fair value assessment of the asset, aggregating professional analyst forecasts to determine fundamental growth potential. By analyzing the history of the consensus target price, an investor can evaluate market expectations regarding the successful completion of Phase 3 trials for the antidepressant drug and the readiness of Relmada Therapeutics (RLMD) for a commercial launch in the US market.
Competitors of Relmada Therapeutics
BIIB (biogen.com) - Fair Value Consensus|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd - Price Target Chart|AXSM - Price Target Chart|ACADIA Corp (ACAD) - Consensus Target|XENE: Analyst Consensus Forecast|Broker Consensus Forecast VKTX|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|ALEC: Fair Value Consensus|Analyst Consensus Forecast ANNX|OMER - Average Forecast Price|Price Target Chart Neurogene Corp NGNE|AC Immune Inc - Price Target Chart|VYGR - Price Target Chart|neumoratx.com (NMRA) - Consensus Target|SCLX: Analyst Consensus Forecast|Tevogen Bio Holdings Inc. (TVGN) - Analyst Consensus Forecast|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|Broker Consensus Forecast CGTX (cogrx.com)|Analyst Consensus Forecast IKT|Analyst Consensus Forecast cassavasciences.com (SAVA)|Assertio - Consensus Target|Fair Value Consensus COYA|VTGN: Consensus Target|Ovid Therapeutics Inc. - Analyst Forecast Prices|ABOS: Analyst Consensus Forecast|cervomed.com - Fair Value Consensus|ATHE (Alterity Therapeutics Ltd.) - Analyst Consensus Forecast|Average Forecast Price Clene Nanomedicine CLNN|Price Target Chart PepGen Inc. (PEPG)|JUNS (jupiterneurosciences.com) - Fair Value Consensus|Analyst Consensus Forecast ANVS (Annovis Bio, Inc.)|Analyst Consensus Forecast Grace Therapeutics Inc GRCE|AIFF - Price Target Chart|Forecast Levels Chart KLTO|NRSN: Analyst Consensus Forecast|Average Forecast Price Reviva Pharmaceuticals, Inc. (RVPH)|Consensus Target MTVA|Analyst Consensus Forecast neuraxis.com|Consensus Target HSDT (Helius Medical)|Analyst Forecast Prices PASG|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|Analyst Median Target Minerva (NERV)|Athira Pharma, Inc. - Analyst Consensus Forecast|addextherapeutics.com (ADXN) - Consensus Target|alzamend.com (ALZN) - Price Target Chart|CYCN - Analyst Median Target|Price Target Chart Protagenic Therapeutics Inc.|KTTA: Fair Value Consensus|Price Target Chart Cortigent, Inc. (CRGT)|Price Target Chart ATXI (avenuetx.com)|Price Target Chart BrainStorm Cell Therapeutics BCLI|CARA - Consensus Target|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|ELYM (Eliem Therapeutics) - Broker Consensus Forecast|intracellulartherapies.com (ITCI) - Price Target Chart|Broker Consensus Forecast LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Average Forecast Price NKGen Biotech Inc NKGN|Consensus Target NRBO (NeuroBo)|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Price Target Chart Synaptogenix, Inc. SNPX|Fair Value Consensus TRVN|VIGL - Price Target Chart|Average Forecast Price Anew Medical Inc.|Cerevel (CERE) - Price Target Chart
